Search

Showing "11155" results for ""

Once-daily nevirapine doesn't improve adherence, may increase risk of treatment break and resistance

EACS proposes list of ‘indicator diseases’ to prompt the offer of an HIV test

EACS: Once-a-day Kaletra can be risky

EACS: Hospital admissions and appointments predict subsequent HIV diagnosis and death

EACS: One in five UK patients remains on failing therapy for over a year

EACS: Growth-hormone drug reduces abdominal fat – if you keep on taking it

EACS: CD4 cells: the lower you start, the lower you finish

EACS: Drugs that get into the brain work better for neurological AIDS diseases

EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance

EACS: Nevirapine studies highlight new first-line uses

EACS: Old campaigners: Belgians document long-term AIDS survival

EACS: Kaletra monotherapy may need excellent adherence to work

Defining, and then watching for, treatment failure

US state laws obstruct CDC recommendations for routine HIV testing

XDR-TB found in HIV-positive patients in India; rapid progression to death

UK report highlights homelessness link to IDUs acquiring hepatitis C, but not HIV

HIV transmission in Africa: high risk groups equally important in early and advanced epidemics

Two and a half years extra ART if treatment starts at 500 CD4s, not 350

Receive the latest HIV research and conference news

Showing "11155" results for ""

Once-daily nevirapine doesn't improve adherence, may increase risk of treatment break and resistance

EACS proposes list of ‘indicator diseases’ to prompt the offer of an HIV test

EACS: Once-a-day Kaletra can be risky

EACS: Hospital admissions and appointments predict subsequent HIV diagnosis and death

EACS: One in five UK patients remains on failing therapy for over a year

EACS: Growth-hormone drug reduces abdominal fat – if you keep on taking it

EACS: CD4 cells: the lower you start, the lower you finish

EACS: Drugs that get into the brain work better for neurological AIDS diseases

EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance

EACS: Nevirapine studies highlight new first-line uses

EACS: Old campaigners: Belgians document long-term AIDS survival

EACS: Kaletra monotherapy may need excellent adherence to work

Defining, and then watching for, treatment failure

US state laws obstruct CDC recommendations for routine HIV testing

XDR-TB found in HIV-positive patients in India; rapid progression to death

UK report highlights homelessness link to IDUs acquiring hepatitis C, but not HIV

HIV transmission in Africa: high risk groups equally important in early and advanced epidemics

Two and a half years extra ART if treatment starts at 500 CD4s, not 350

Receive the latest HIV research and conference news